Bayer has announced a partnership with deep-tech startup Impli to advance the development of what could become the first real-time hormone monitoring device. The collaboration aims to make fertility treatment more accessible, safer, and more successful while exploring broader applications of hormone monitoring technology.
The partnership follows Impli’s win at a Bayer-sponsored innovation challenge during the HLTH Europe conference earlier this year. While specific terms remain undisclosed, the partnership will focus on advancing early-stage research and exploring various use cases for hormone monitoring. Importantly, Impli will gain access to Bayer’s global innovation ecosystem.
“New technologies are helping us answer one of the largest consumer unmet needs: better understanding what is happening in their own body and what it means for managing their health journey,” said Aquil Harjivan, Head of front-end innovation for the Consumer Health division of Bayer. “We are excited to join cutting-edge innovators like Impli to explore the exciting frontiers of making health care more precise for every individual.”
The collaboration is particularly significant as it could impact multiple health areas beyond fertility. Bayer has indicated interest in applications across various self-care categories, including stress, sleep, weight management, cardiovascular health, women’s health, and bone health – all areas where hormonal insights could prove valuable.
“Reimagining women’s hormonal health is more than a challenge; it’s an opportunity to innovate and transform lives. The opportunity to break barriers together with a pioneering leader in the field such as Bayer is not just exciting—it’s a chance to create meaningful change and deliver better outcomes for everyone,” said Anna Luisa Schaffgotsch CEO, Impli.
This partnership is part of Bayer’s broader push into precision health, following the launch of their dedicated business unit in this space. Earlier this year, the company introduced the One-a-Day Age Factor ecosystem in the U.S.